Amytrx Therapeutics has filed a notice of an exempt offering of securities to raise $6,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Amytrx Therapeutics is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Mathew Gonda…